Arbaclofen in fragile X syndrome: results of phase 3 trials

Arbaclofen in fragile X syndrome: results of phase 3 trials

Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is to determine safety and efficacy of arbaclofen for social avoidance in FXS. Methods: Two phase 3 placebo-c...

Full description

Bibliographic Details
Main Authors: Berry-Kravis, Elizabeth, Hagerman, Randi, Visootsak, Jeannie, Budimirovic, Dejan, Kaufmann, Walter E., Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Wang, Paul, Bear, Mark, Carpenter, Randall L
Other Authors: Picower Institute for Learning and Memory
Format: Article
Published: Springer-Verlag 2017
Online Access:http://hdl.handle.net/1721.1/112102
https://orcid.org/0000-0002-9072-5923

Internet

http://hdl.handle.net/1721.1/112102
https://orcid.org/0000-0002-9072-5923

Similar Items